AU Patent

AU2019474273B2 — Injection end point signalling assembly for pre-filled syringes

Assigned to Biocorp Production SAS · Expires 2023-04-20 · 3y expired

What this patent protects

An injection endpoint signalling assembly is provided that is adapted and configured for mounting on, and use with, a pre-filled syringe. The injection endpoint assembly is configured to prevent a signalling of an injection endpoint before the plunger of the pre-filled syringe ha…

USPTO Abstract

An injection endpoint signalling assembly is provided that is adapted and configured for mounting on, and use with, a pre-filled syringe. The injection endpoint assembly is configured to prevent a signalling of an injection endpoint before the plunger of the pre-filled syringe has reached a limit of a permitted extent of a direction of injection travel. The assembly is further configured to enable the signalling of the injection end point when the plunger of the pre-filled syringe has reached the limit of the permitted extent of the direction of injection travel and is prevented from moving in a direction of travel different to the direction of injection travel.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019474273B2
Jurisdiction
AU
Classification
—
Expires
2023-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Biocorp Production SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.